p19 INK4D/CDKN2D Antibody (3H2796): sc-71808
- p19 INK4D/CDKN2D Antibody (3H2796) is a mouse monoclonal IgG1 κ provided at 200 µg/ml
- raised against full length p19 INK4D of human origin
- recommended for detection of p19 of human origin by WB, IP, IF and ELISA
- m-IgG Fc BP-HRP and m-IgG1 BP-HRP are the preferred secondary detection reagents for p19 INK4D/CDKN2D Antibody (3H2796) for WB applications. These reagents are now offered in bundles with p19 INK4D/CDKN2D Antibody (3H2796) (see ordering information below).
QUICK LINKS
SEE ALSO...
p19 INK4D Antibody (3H2796) is a mouse monoclonal IgG1 antibody that detects p19 INK4D in human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). p19 INK4D plays a crucial role in regulating the cell cycle by specifically inhibiting the kinase activities of cyclin-dependent kinases Cdk4 and Cdk6, which are essential for the transition from the G1 phase to the S phase of the cell cycle. This inhibition helps prevent uncontrolled cell proliferation, a hallmark of cancer. p19 INK4D expression reaches maximum levels during the S phase, and p19 INK4D overexpression can lead to G1 arrest, acting as a critical checkpoint in cellular growth and division. The gene encoding p19 INK4D is located on chromosome 9p21.3, a region frequently associated with chromosomal abnormalities in various human tumors, highlighting p19 INK4D′s potential significance in cancer research and therapeutic applications. Anti-p19 INK4D antibody (3H2796) serves as an invaluable tool for researchers studying cell cycle regulation and the molecular mechanisms underlying tumorigenesis.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
p19 INK4D/CDKN2D Antibody (3H2796) References:
- Mutation testing in melanoma families: INK4A, CDK4 and INK4D. | Newton Bishop, JA., et al. 1999. Br J Cancer. 80: 295-300. PMID: 10390011
- Increased expression of unmethylated CDKN2D by 5-aza-2'-deoxycytidine in human lung cancer cells. | Zhu, WG., et al. 2001. Oncogene. 20: 7787-96. PMID: 11753657
- Histone deacetylase inhibitors activate INK4d gene through Sp1 site in its promoter. | Yokota, T., et al. 2004. Oncogene. 23: 5340-9. PMID: 15107822
- Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells. | Ceruti, JM., et al. 2005. Oncogene. 24: 4065-80. PMID: 15750620
- Cell cycle inhibitor, p19INK4d, promotes cell survival and decreases chromosomal aberrations after genotoxic insult due to enhanced DNA repair. | Scassa, ME., et al. 2007. DNA Repair (Amst). 6: 626-38. PMID: 17218167
- p19Ink4d and p18Ink4c cyclin-dependent kinase inhibitors in the male reproductive axis. | Buchold, GM., et al. 2007. Mol Reprod Dev. 74: 997-1007. PMID: 17342741
- p19Ink4d is a tumor suppressor and controls pituitary anterior lobe cell proliferation. | Bai, F., et al. 2014. Mol Cell Biol. 34: 2121-34. PMID: 24687853
- MiR-451 inhibits proliferation of esophageal carcinoma cell line EC9706 by targeting CDKN2D and MAP3K1. | Zang, WQ., et al. 2015. World J Gastroenterol. 21: 5867-76. PMID: 26019450
- LncRNA CRNDE promotes the progression and angiogenesis of pancreatic cancer via miR-451a/CDKN2D axis. | Zhu, HY., et al. 2021. Transl Oncol. 14: 101088. PMID: 33882369
- Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4. | Guan, KL., et al. 1996. Mol Biol Cell. 7: 57-70. PMID: 8741839
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
p19 INK4D/CDKN2D Antibody (3H2796) | sc-71808 | 200 µg/ml | $316.00 | |||
p19 INK4D/CDKN2D Antibody (3H2796): m-IgG Fc BP-HRP Bundle | sc-539409 | 200 µg Ab; 10 µg BP | $354.00 | |||
p19 INK4D/CDKN2D Antibody (3H2796): m-IgG1 BP-HRP Bundle | sc-541474 | 200 µg Ab; 20 µg BP | $354.00 |